Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2024 > Vol 5, №10 (2024) > A clinical case of diagnosis of pulmonary hypertension in a patient with comorbid pathology

A clinical case of diagnosis of pulmonary hypertension in a patient with comorbid pathology

Elena V. Usacheva , Elena V. Nadey , Anastasiya V. Shkirinets , Ekaterina E. Nakonechnaya , Olga V. Zamachina , Elena A. Temereva , Irina Yu. Botvinko

For citation:


  • Abstract
  • About the Author
  • References

Abstract

Currently, there is an increase in the frequency of comorbid conditions, which are accompanied by a change in the clinical picture of the course of diseases, insufficient effectiveness of standard therapy, and an increased risk of progression and development of complications of existing diseases. The article presents a clinical case of diagnosis of pulmonary hypertension in a patient with comorbid pathology. This case demonstrates the identification of systemic connective tissue disease and pulmonary hypertension in a patient who already has pathology of the cardiovascular, nervous and endocrine systems and metabolic disorders requiring complex therapy with justified polypharmacy in this case and mutually exclusive requirements for the control of various diseases. Only a joint discussion of the tactics of patient management by doctors of different specialties allows therapist to develop an optimal treatment plan, prevent adverse drug interactions, contributing to improving the quality and increasing the life expectancy of patients with comorbid pathology.
Keywords: pulmonary hypertension, multiple sclerosis, scleroderma, systemic connective tissue diseases, interferon, comorbid pathology, Raynaud's syndrome, angina pectoris, pain due to the dilation of the pulmonary artery.

About the Author

Elena V. Usacheva 1 , Elena V. Nadey 1 , Anastasiya V. Shkirinets 2 , Ekaterina E. Nakonechnaya 3 , Olga V. Zamachina 1 , Elena A. Temereva 1 , Irina Yu. Botvinko 4

1 Omsk State Medical University, Omsk, Russia

2 Omsk State Medical University, Omsk, Russia; Budget-Financed Healthcare Institution of the Omsk Region "Clinical Cardiology Dispensary", Omsk, Russia

3 Budget-Financed Healthcare Institution of the Omsk Region "Clinical Cardiology Dispensary", Omsk, Russia

4 Budgetary Healthcare Institution of the Omsk Region "Clinical medical and sanitary unit No. 7", Omsk, Russia

References

1. Драпкина О.М., Концевая А.В., Калинина А.М. и др. Коморбидность пациентов с хроническими неинфекционными заболеваниями в практике врача-терапевта. Евразийское руководство. Кардиоваскулярная терапия и профилактика. 2024;23(3):3696. Drapkina O.M., Kontsevaya A.V., Kalinina A.M. et al. Comorbidity of patients with chronic non-communicable diseases in the practice of a general practitioner. The Eurasian leadership. Cardiovascular therapy and prevention. 2024;23(3):3696 (in Russian).
2. Оганов Р.Г., Денисов И.Н., Симаненков В.И. и др. Коморбидная патология в клинической практике. Клинические рекомендации. Кардиоваскулярная терапия и профилактика. 2017;16(6):5-56. Oganov R.G., Denisov I.N., Simanenkov V.I. et al. Comorbid pathology in clinical practice. Clinical recommendations. Cardiovascular therapy and prevention. 2017;16(6):5-56 (in Russian).
3. Трактирская О.А., Попова Е.В., Лащ Н.Ю. и др. Коморбидная патология сердечно-сосудистой системы у молодых пациентов с ремиттирующим течением рассеянного склероза. Журнал неврологии и психиатрии им. С.С. Корсакова. 2019;119(10, вып. 2):72-80. Traktirskaya O.A., Popova E.V., Lasch N.Yu. et al. Comorbid pathology of the cardiovascular system in young patients with a remitting course of multiple sclerosis. Journal of Neurology and Psychiatry named after S.S. Korsakov. 2019;119(10, issue 2):72-80 (in Russian).
4. International Multiple Sclerosis Genetics Consortium; MultipleMS Consortium. Locus for severity implicates CNS resilience in progression of multiple sclerosis. Nature 2023;619(7969):323-31.
5. Haque A, Kiely DG, Kovacs G et al. Condliffe R. Pulmonary hypertension phenotypes in patients with systemic sclerosis. Eur Respir Rev 2021;30(161):210053.
6. McGee M, Whitehead N, Martin J, Collins N. Drug-associated pulmonary arterial hypertension. Clin Toxicol (Phila) 2018 Sep;56(9):801-9.
7. Mandras SA, Mehta HS, Vaidya A. Pulmonary Hypertension: A Brief Guide for Clinicians. Mayo Clin Proc 2020;95(9):1978-1988.
8. Anand S, Sadek A, Vaidya A, Oliveros E. Diagnostic Evaluation of Pulmonary Hypertension: A Comprehensive Approach for Primary Care Physicians. J Clin Med 2023;12(23):7309.
9. Khangoora V, Bernstein EJ, King CS, Shlobin OA. Connective tissue disease-associated pulmonary hypertension: A comprehensive review. Pulm Circ. 2023;13(4):e12276.
10. Волков А.В. Легочная артериальная гипертензия при системных заболеваниях соединительной ткани. Научно-практическая ревматология. 2015;53(1):69-77. Volkov AV. Pulmonary arterial hypertension in systemic connective tissue diseases. Scientific and practical rheumatology. 2015;53(1):69-77 (in Russian).
11. Khangoora V, Bernstein EJ, King CS, Shlobin OA. Connective tissue disease-associated pulmonary hypertension: A comprehensive review. Pulm Circ 2023;13(4):e12276.
12. Bahi M, Li C, Wang G, Korman BD. Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: From Bedside to Bench and Back Again. Int J Mol Sci 2024;25(9):4728.
13. Tuhy T, Hassoun PM. Clinical features of pulmonary arterial hypertension associated with systemic sclerosis. Front Med (Lausanne) 2023;10:1264906.
14. Charkiewicz AE, Backstrand JR. Lead Toxicity and Pollution in Poland. Int J Environ Res Public Health. 2020;17(12):4385.
15. Цепкова Г., Власенко А. Хронические профессиональные заболевания, обусловленные воздействием наиболее распространенных органических растворителей. Врач. 2018;29(7):19-26. Tsepkova G, Vlasenko A. Chronic occupational diseases caused by exposure to the most common organic solvents. Doctor. 2018;29(7):19-26 (in Russian).
16. Caliez J, Riou M, Manaud G et al. Trichloroethylene increases pulmonary endothelial permeability: implication for pulmonary veno-occlusive disease. Pulm Circ 2020;10(4):2045894020907884.
17. Voudris V. Pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis. Case report and literature review. Mult Scler Relat Disord 2019;28:273-275.
18. Fok A, Williams T, McLean CA. et al. Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients. Mult Scler Epub 2016;22(11):1495-8.
19. Papani R, Duarte AG, Lin YL, Kuo YF, Sharma G. Pulmonary arterial hypertension associated with interferon therapy: a population-based study. Multidiscip Respir Med 2017 Jan 17;12:1.
20. Cansu DÜ, Korkmaz C. Pulmonary hypertension in connective tissue diseases: epidemiology, pathogenesis, and treatment. Clin Rheumatol 2023 Oct;42(10):2601-2610. DOI: 10.1007/s10067-022-06446-y.

For citation:Usacheva E.V., Nadey E.V., Shkirinets A.V., Nakonechnaia E.E., Zamahina O.V., Temereva E.A., Botvinko I.U. A clinical case of diagnosis of pulmonary hypertension in a patient with comorbid pathology. Clinical review for general practice. 2024; 5 (10): 39–45 (In Russ.). DOI: 10.47407/kr2024.5.10.00494


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru